



## **ImaBiotech hires Florian Barré as Business Developer Europe, Europe.**

**Lille, 17<sup>th</sup> January 2019**

ImaBiotech CORP is pleased to announce the hiring of Florian Barré as new Business Developer Europe. During his Ph.D. at Maastricht University (The Netherlands), he developed innovative mass spectrometry-based approaches and methods to detect pharmaceuticals in tissue using state-of-the-art mass spectrometry imaging (MSI).

Dr. Florian Barré has been trained as a Researcher since his Bachelor degree specialized in cell biology and physiology at the University of Lille (France). Then, he took a Proteomics Master at the same place and gained a lot of knowledge through his numerous trainings focused on Mass Spectrometry, MALDI Imaging, and Medicine.

As a Marie Curie Early Stage Research Fellow at Maastricht MultiModal Molecular Imaging Institute (M4I) of Maastricht University, Division of imaging mass spectrometry, under the supervision of Prof. Ron Heeren and Dr. Berta Cillero Pastor. He contributed developing a new MALDI source for high speed and spatial resolution in collaboration with a mass spectrometry company (Waters). He also studied the evaluation of advanced drug delivery carriers using MSI and worked on innovative sample preparation for drug detection including on-tissue chemistry and new instrumental development such as postionization MALDI (MALDI-2). In addition, he was an Imaging Consultant for a private company (HTX Imaging) and collaborated with drug discovery teams of pharmaceutical companies bringing his expertise in MSI to study small molecule distribution in biological samples. He has also been involved in the MSI community as organizer of workshops and conferences (OurCon 2017).

As Business Developer for South-Europe including (France, Belgium, Italy, Spain, Switzerland,...), he is responsible for ImaBiotech european commercial activities. He is as well in charge of building and maintaining successful relationships with prospects and existing customers in early phase (Preclinical - Drug Discovery, ADME, DMPK, and Toxicology) and late phase (Clinical) development while conducting a market analysis to identify target customers.

« *His motivation and scientific knowledge will be a huge asset for the company* » says Jonathan Stauber, ImaBiotech's founder.

Publications by Dr. F.Barré

TITLE	AUTORS	REVIEW	DATE OF PUBLICATION
<b>Spatially resolved proteomics in osteoarthritis: State of the art and new perspectives</b>	<i>MR Eveque-Mourroux, B Rocha, FPY Barré, RMA Heeren, B Cillero-Pastor</i>	Journal of Proteomics	2020/1/9
<b>Advanced Mass Spectrometry Imaging: Pharmaceutical distributions and effects from Cartilage to Cancer</b>	<i>Florian PY Barré</i>		2019
<b>Enhanced sensitivity using MALDI imaging coupled with laser postionization (MALDI-2) for pharmaceutical research</b>	<i>Florian PY Barré, Martin RL Paine, Bryn Flinders, Adam J Trevitt, Patrick D Kelly, Rima Ait-Belkacem, João P Garcia, Laura B Creemers, Jonathan Stauber, Rob J Vreeken, Berta Cillero-Pastor, Shane R Ellis, Ron MA Heeren</i>	Analytical Chemistry	2019/7/29
<b>Development and evaluation of matrix application techniques for high throughput mass spectrometry imaging of tissues in the clinic</b>	<i>Lennart RS Huizing, Shane R Ellis, Bart WAMM Beulen, Florian PY Barré, Paul B Kwant, Rob J Vreeken, Ron MA Heeren</i>	Clinical Mass Spectrometry	2019/4/1
<b>Specific Lipid and Metabolic Profiles of R-CHOP-Resistant Diffuse Large B-Cell Lymphoma Elucidated by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and in Vivo Imaging</b>	<i>Berta Cillero-Pastor Florian P.Y. Barré, Britt S.R. Claes, Frédéric Dewez, Carine J. Peutz-Kootstra, Helga F. Munch-Petersen, Kirsten Grønbaek, Anders Lund, Ron M.A. Heeren, Christophe Roger Michel Côme</i>		2018/11/13

<b>Faster raster matrix-assisted laser desorption/ionization mass spectrometry imaging of lipids at high lateral resolution</b>	<i>Tiffany Porta Siegel Florian Barré, Beatriz Rocha, Frédéric Dewez, Mark Towers, Paul Murray, Emmanuelle Claude, Berta Cillero-Pastor, Ron Heeren</i>		2018/9
<b>Distribution, quantification and effects of triamcinolone acetonide in human osteoarthritic cartilage</b>	<i>FP Barré, M Paine, B Flinders, M Eveque-Mourroux, J Garcia, S Ellis, RM Heeren, L Creemers, B Cillero Pastor</i>	Osteoarthritis and Cartilage	2018/4/1
<b>The paradoxical effects of chronic intra-amniotic Ureaplasma parvum exposure on ovine fetal brain development</b>	<i>Ruth Gussenhoven, Daan RMG Ophelders, Matthew W Kemp, Matthew S Payne, Owen B Spiller, Michael L Beeton, Sarah J Stock, Bertha Cillero-Pastor, Florian PY Barré, Ron MA Heeren, Lilian Kessels, Bas Stevens, Bart P Rutten, Suhas G Kallapur, Alan H Jobe, Boris W Kramer, Tim GAM Wolfs</i>	Developmental neuroscience	2017
<b>Mass Spectrometry Imaging in Nanomedicine: Unraveling the Potential of MSI for the Detection of Nanoparticles in Neuroscience</b>	<i>Florian PY Barre, Ron MA Heeren, Nina Ogrinc Potocnik</i>	Current Pharmaceutical Design	2017/4/1
<b>Derivatization strategies for the detection of triamcinolone acetonide in cartilage by using matrix-assisted laser desorption/ionization mass spectrometry imaging</b>	<i>Florian PY Barré, Bryn Flinders, João P Garcia, Imke Jansen, Lennart RS Huizing, Tiffany Porta, Laura B Creemers, Ron MA Heeren, Berta Cillero-Pastor</i>	Analytical chemistry	2016/12/2

#### About ImaBiotech:

ImaBiotech is a Contract Research Organization (CRO) with facilities in Boston (MA, USA) and Lille (Eurasanté Parc, France). The company offers innovative services and software to the pharmaceutical research sector, providing highly in vivo-informative drug efficacy and toxicity evaluations during preclinical and clinical stage developments at cellular level, making better and safer drugs. Services are based on histology combined to label free molecular imaging (Quantitative Mass Spectrometry Imaging, QMSI) a technology developed and constantly improved by ImaBiotech. QMSI is a game changer for the pharmaceutical industry in all therapeutic areas. While other techniques provide global information, this molecular technique provides a deeper understanding of a drug's localization and its pharmacological effects at cellular level. This improves the interpretation of drug efficacy and toxicity, resulting in better drugs and decreasing time-to-market.

To learn more about ImaBiotech:

- Edma Fontaine –Communication and Marketing Manager
- fontaine.edma@imabiotech.com-+33 (0) 374095546
- [www.ImaBiotech.com](http://www.ImaBiotech.com)